Goldman Throws in the Towel on Nektar After $14 Billion Drop
(Bloomberg) -- Nektar Therapeutics bull Goldman Sachs is calling it quits after recommending shares since December despite the stock's slide and subsequent removal from the S&P 500 Index.
Goldman's Paul Choi downgraded shares two notches, to a sell from buy, citing a lack of near-term catalysts amid drug quality issues and a narrower investor focus for its cancer drug among recent pressures on the stock. He slashed his price target to a Street-low of $16 from $54, which had implied shares could nearly triple from current levels.
Nektar fell as much as 10% Tuesday, its biggest drop since Aug. 12. The shares have lost more than half their value since Choi initiated coverage in December, compared to a 10% rise for the S&P 500 Index. The stock has shed more than $14 billion from a March 2018 peak.
The drugmaker's manufacturing snafu that pressured shares in August and raised investor uncertainty paired with a heightened focus on Nektar's ability to execute late-stage drug development drove Choi to finally throw in the towel. “Nektar now faces significant challenges in rebuilding confidence in the clinical and commercial outlook for” its experimental cancer drug bempegaldesleukin in combination with Bristol-Myers Squibb Co.'s Opdivo, he wrote.
Read more: Nektar Went From S&P 500 Darling to Reject in 18 Months
Short bets against the biotech firm have risen over the last year with more than 17% of shares available for trading currently sold short, data compiled by financial analytics firm S3 Partners show.
Nektar wasn't the only casualty among Choi's coverage. He separately downgraded shares of beleaguered Puma Biotechnology Inc. to sell from neutral and slashed his price target to $8 from $24. Potential competition for the company's cancer drug Nerlynx is an underappreciated investor risk, he said. The stock fell 18% Tuesday and has lost 82% in the last year.
--With assistance from Joshua Fineman.
To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.net
To contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Courtney Dentch
©2019 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.